Abstract 322: Nonclinical characterization of the secondary mechanisms of action of PF-08046054 (PDL1V), a novel vedotin ADC directed to PD-L1 that selectively depletes tumor cells without depleting healthy immune cells
Year: 2025
Type: conference-abstract
Source: Cancer Research
Institution: Pfizer (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409691091